产品名称 | NebuPeptide™ Eptifibatide (Peptide Reference) 依替巴肽 |
---|---|
目录号 | NBS-233796 |
别名 | |
外观 | White to off-white solid powder |
分子量 | 831.96 |
CAS | 188627-80-7 |
溶解度 | see COA |
存储条件 | Store at -20℃ |
保存时间 | see COA |
备注1 | |
备注2 |
目录号 | 规格 | 价格 | 库存状态 | |
NBS-233796-1mg | 1mg | 咨询 | 现货 | |
NBS-233796-5mg | 5mg | 咨询 | 现货 | |
NBS-233796-100mg | 100mg | 咨询 | 现货 | |
NBS-233796-1g | 1g | 咨询 | 现货 | |
NBS-233796-Bulk | Bulk | 咨询 | 咨询 |
Product Name:
NebuPeptide™ Eptifibatide (Peptide Reference)
Catalog Number:
NBS-233796
Description:
NebuPeptide™ Eptifibatide (Peptide Reference)(CAT#NBS-233796) is synthesized in accordance with the Eptifibatide sequence and can be utilized for a variety of in vivo and in vitro studies, including quality control, bioactivity verification, immunization, drug development, structural analysis, etc. Nebula Biotechnology Co., Ltd. is capable of providing Ganirelix Acetate reference peptide ranging from milligrams to kilograms.
Peptide Name:
Eptifibatide (依替巴肽)
Background:
Eptifibatide is a potent glycoprotein IIb/IIIa antagonist (GPIIb/IIIa; Kd = 120 nM) that inhibits platelet aggregation. Eptifibatide prevents binding of the adhesion proteins fibrinogen and von Willebrand factor to GPIIb/IIIa on the surface of activated platelets to prevent aggregation and thrombus formation. It inhibits ADP-induced citrated blood aggregation (IC50 = 0.11-0.22 μg/ml) in vitro and in vivo (IC50 = 52 μg/ml in porcine plasma). Formulations containing eptifibatide have been used to reduce risk of thrombolysis in myocardial infarction in patients undergoing percutaneous coronary intervention.
Alias:
N/A
CAS Number:
188627-80-7
Formula:
C35H49N11O9S2
Molecular Weight:
831.96
Purity:
see COA
Solubility:
see COA
Storage & Shipment:
Store at -20℃; ship with blue ice.
For R&D use only!
To get more information, please contact us freely.